Aclaris Therapeutics has decided to give its MK2 inhibitor zunsemetinib a second chance—unfortunately, almost half of the biotech’s workforce won’t be so lucky.
” Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis ” ” Efficacy Results Do Not Support Further Development of Zunsemetinib ” ” Company to Host Conference Call and...
- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...